Occam Places CBO for Oncology Biotech Accent Therapeutics
In September 2018, Occam recruited David Brower as Chief Business Officer of Accent Therapeutics, a developer of biomarker-driven cancer medicines.
David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, he led the business development function for Blueprint Medicines, where he completed various strategic transactions, including its seminal partnerships with Roche Pharmaceuticals, CStone Pharmaceuticals, and Alexion Pharmaceuticals. Prior to Blueprint Medicines, David was a member of Pfizer Pharmaceuticals’ Worldwide Business Development team, focusing on licensing and M&A transactions and business development strategy. David began his career as a healthcare trader and investor for Lehman Brothers and Barclays Capital.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.